SOLV says HIS separation keeps 4%-5% organic growth target to 2028
Management said the HIS separation is for strategic focus on medtech, keeping RemainCo’s 4%-5% organic growth target by 2028 intact. Margin dilution is expected, with efficiencies and new launches supporting MedSurg and Dental margin and EPS expansion.
Management said the HIS separation is intended to sharpen strategic focus on medtech, while RemainCo’s 4%-5% organic growth target through 2028 remains unchanged. The company said margin dilution is expected, but cited operational efficiencies, new product launches, and growth in MedSurg and Dental as support for margin and EPS expansion.